Absci (Nasdaq: ABSI), a generative AI drug creation company, and
PrecisionLife®, a leading computational biology company driving
precision medicine in complex chronic diseases, today announced a
collaboration to develop a joint portfolio of potential
therapeutics addressing unmet medical needs. The collaboration
combines Absci’s speed and strength in antibody design and
optimization with PrecisionLife’s deep understanding of complex
disease biology and expertise in identifying the mechanisms, drug
targets and treatments that are relevant to specific patients to
create a pipeline of novel biotherapeutics.
Under the partnership, Absci and PrecisionLife will work
together to discover and develop a shared pipeline of
biotherapeutics for up to five mutually agreed-upon targets and
indications, then jointly evaluate options to most effectively
advance programs against such targets. Absci and PrecisionLife will
actively collaborate to select chronic disease drug targets linked
to patients with unmet clinical needs and maximize the innovation
potential of their respective approaches. The Partners will share
in the potential value of programs developed against any specific
targets.
“Absci’s partnership with PrecisionLife combines our
complementary strengths with the aim of creating a high-value
pipeline of novel therapeutics,” said Sean McClain, Absci Founder
& CEO. “PrecisionLife’s exceptional ability to unravel complex
disease biology complements our AI-driven approach, enabling us to
jointly accelerate the development of potentially effective
therapeutics for the patients who need them.”
"PrecisionLife is excited to partner with Absci," said Steve
Gardner, CEO & Co-founder of PrecisionLife. "Our partnership
demonstrates the transformational innovation potential of coupling
leading generative AI approaches with PrecisionLife’s unique
disease biology insights to accelerate and de-risk the development
of new precision medicines for patients with unmet medical
needs."
With this new partnership, Absci has now signed ten new Active
Programs this year, achieving the Company’s outlook for 2023.
About Absci
Absci is a generative AI drug creation company that combines AI
with scalable wet lab technologies to create better biologics for
patients, faster. Our Integrated Drug Creation™ platform unlocks
the potential to accelerate time to clinic and increase the
probability of success by simultaneously optimizing multiple drug
characteristics important to both development and therapeutic
benefit. With the data to learn, the AI to create, and the wet lab
to validate, Absci can screen billions of cells per week, allowing
it to go from AI-designed antibodies to wet lab-validated
candidates in as little as six weeks. Absci’s vision is to deliver
breakthrough therapeutics at the click of a button, for everyone.
Absci’s headquarters is in Vancouver, WA, its AI Research Lab is in
New York City, and its Innovation Center is in Zug, Switzerland.
Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter)
(@Abscibio), and YouTube.
Absci Media Contactpress@absci.com
Absci Investor ContactAlex Khan, VP, Finance
& Investor
Relations
investors@absci.com
About PrecisionLife
PrecisionLife® is a pioneering precision medicine company
changing the way the world predicts, prevents, and treats complex
chronic diseases. We seek partners committed to finding better,
more personalized treatment options for patients across the
biopharma and healthcare value chain.
Our combinatorial analytics platform understands disease biology
better, identifying disease mechanisms that are relevant to
specific patients and the drug targets and treatments that would
benefit them.
These unique insights enable us to discover new subgroups of
patients with mechanism-based patient stratification biomarkers,
identify novel treatment opportunities for unmet medical needs,
de-risk and accelerate clinical trials, find new applications for
existing drug programs, build highly predictive complementary
diagnostics, and personalize risk prediction and disease
prevention.
To learn more about our groundbreaking work, please visit
precisionlife.com, and follow us on LinkedIn (@PrecisionLifeAI) and
X/Twitter (@PrecisionLifeAI).
PrecisionLife Media Contact:Noah Konig,
Marketing Directornoah@precisionlife.com / +44 (0)1865 575170
Availability of Other Information about
Absci
Investors and others should note that we routinely communicate
with investors and the public using our website (www.absci.com) and
our investor relations website (investors.absci.com), including
without limitation, through the posting of investor presentations,
SEC filings, press releases, public conference calls and webcasts
on these websites, as well as on X (Twitter), LinkedIn and YouTube.
The information that we post on these websites and social media
outlets could be deemed to be material information. As a result,
investors, the media, and others interested in Absci are encouraged
to review this information on a regular basis. The contents of our
website and social media postings, or any other website that may be
accessed from our website or social media postings, shall not be
deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended.
Absci Forward-Looking Statements
Certain statements in this press release that are not historical
facts are considered forward-looking within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including
statements containing the words “will,” “may,” “pursues,”
“anticipates,” “plans,” “believes,” “aims,” “potential,”
“forecast,” “estimates,” “extends,” “expects,” and “intends,” or
similar expressions. We intend these forward-looking statements,
including statements regarding technology development efforts and
the application of those efforts, including acceleration of drug
development timelines, reducing the time and costs related to drug
development, advancements toward drug discovery and development
activities, the potential benefits of our partnership with
PrecisionLife, the success of our partnerships and their ability to
generate scientific and technical insights for using AI drug
creation to accelerate the development of candidate therapies,
developing a diverse, high-value portfolio of novel drug
treatments, and the anticipated value to us under our partnership,
to be covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act, and we make this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements reflect our current
views about our plans, intentions, expectations, strategies, and
prospects, which are based on the information currently available
to us and on assumptions we have made. We can give no assurance
that the plans, intentions, expectations, or strategies will be
attained or achieved, and furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control, including, without limitation, risks and
uncertainties relating to our ability to effectively collaborate on
research, drug discovery and development activities with our
partners or potential partners; our existing and potential
partners’ ability and willingness to pursue the development and
commercialization of programs or product candidates under the terms
of our partnership agreements; and overall market conditions and
regulatory developments that may affect our and our partners’
activities under these agreements, along with those risks set forth
in our most recent periodic report filed with the U.S. Securities
and Exchange Commission, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the U.S. Securities and Exchange Commission. Except as
required by law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
AbSci (NASDAQ:ABSI)
過去 株価チャート
から 4 2024 まで 5 2024
AbSci (NASDAQ:ABSI)
過去 株価チャート
から 5 2023 まで 5 2024